Teva, Cephalon Gets $72 Million EU Fine for Pay-for-Delay
- Pact stalled sales of cheaper versions of a sleeping drug
- Teva says it will appeal the penalty at the EU’s General Court
This article is for subscribers only.
Teva Pharmaceutical Industries Ltd. and its Cephalon unit were fined 60.5 million euros ($72 million) by the European Union for a pact that delayed sales of a cheaper version of a sleep-disorder drug.
Teva received cash payments and struck beneficial commercial side deals with Cephalon that stopped it rolling out a generic version of Cephalon’s modafinil medicine, the European Commission said Thursday in an emailed statement. Their pay-for-delay pact lasted from 2005 until 2011, when Teva bought Cephalon for $6.2 billion.